Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roy Strowd

Showing results (51-60 of 53) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 53 results.
Science Translational Medicine|October 29, 2025
Leukocyte-intrinsic ER stress responses contribute to chemotherapy-induced peripheral neuropathyMiriam M Fonseca, Oriana Gelblung, Sarah D Pennypacker, et al.
Science Translational Medicine|February 19, 2025
A window-of-opportunity trial reveals mechanisms of response and resistance to navtemadlin in patients with recurrent glioblastomaVeronica Rendo, Eudocia Q Lee, Connor Bossi, et al.
Neuro-Oncology|March 22, 2025
A multi-institutional phase 1 clinical trial exploring upfront multimodal standard of care and combined immunotherapies for newly diagnosed glioblastomaPatrick Y Wen, Andrea Manzanera, Caroline Duault, et al.
Pageof 6

Showing results (51-60 of 53) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 53 results.
Science Translational Medicine|October 29, 2025
Leukocyte-intrinsic ER stress responses contribute to chemotherapy-induced peripheral neuropathyMiriam M Fonseca, Oriana Gelblung, Sarah D Pennypacker, et al.
Science Translational Medicine|February 19, 2025
A window-of-opportunity trial reveals mechanisms of response and resistance to navtemadlin in patients with recurrent glioblastomaVeronica Rendo, Eudocia Q Lee, Connor Bossi, et al.
Neuro-Oncology|March 22, 2025
A multi-institutional phase 1 clinical trial exploring upfront multimodal standard of care and combined immunotherapies for newly diagnosed glioblastomaPatrick Y Wen, Andrea Manzanera, Caroline Duault, et al.
Pageof 6